STOCK TITAN

Ensysce Biosciences Inc Stock Price, News & Analysis

ENSC Nasdaq

Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.

Ensysce Biosciences Inc (NASDAQ: ENSC) is a clinical-stage pharmaceutical innovator developing safer opioid therapies through its patented TAAP and MPAR technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in addressing prescription drug abuse.

Access real-time information about clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated collection features press releases covering product development breakthroughs, intellectual property updates, and operational developments in pain management solutions.

Key content includes updates on abuse-deterrent formulation testing, FDA communication statuses, manufacturing collaborations, and financial performance reports. All materials maintain strict compliance with financial disclosure regulations while emphasizing patient safety advancements.

Bookmark this page for streamlined tracking of ENSC's mission to transform opioid therapy through biochemical innovation and rigorous clinical validation. Check regularly for verified updates directly from corporate communications and authorized news sources.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.11%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.48%
Tags
none
Rhea-AI Summary

Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced that CEO Dr. Lynn Kirkpatrick will speak at a webinar titled ‘Strategies for Achieving Regulatory Milestones Faster’ on April 19, 2023, at 11:30 am ET. The webinar will highlight the integration of Quotient Sciences in developing PF614-MPAR, a novel opioid therapeutic for chronic pain designed to minimize abuse and overdose risks. Dr. Kirkpatrick will address the potential impact of MPAR on future pain management and share insights on Ensysce's collaboration with Quotient. Ensysce is committed to developing safer prescription drugs through innovative technologies like TAAP and MPAR, which are underpinned by substantial intellectual property protections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.59%
Tags
conferences

FAQ

What is the current stock price of Ensysce Biosciences (ENSC)?

The current stock price of Ensysce Biosciences (ENSC) is $2.17 as of May 9, 2025.

What is the market cap of Ensysce Biosciences (ENSC)?

The market cap of Ensysce Biosciences (ENSC) is approximately 4.2M.
Ensysce Biosciences Inc

Nasdaq:ENSC

ENSC Rankings

ENSC Stock Data

4.23M
1.55M
0.83%
10.02%
2.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA